Regulatory milestones

BioDelivery Sciences International Inc. (NASDAQ:BDSI) gained $2.36 (24%) to $12.36 last week after FDA approved Bunavail buprenorphine naloxone as maintenance treatment for opioid dependence. BioDelivery said it plans to launch the product late next quarter.